Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Media section/ covid Immunity Passport Page
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(43)
•••
Comment by Thenorth1990on Nov 04, 2021 10:16pm
127 Views
Post# 34090162

RE:RE:RE:RE:RE:Media section/ covid Immunity Passport Page

RE:RE:RE:RE:RE:Media section/ covid Immunity Passport Page - So initial announcement was around March 2020 and now Said expected revenue in q3 /q4 2020. - without any shame they went on to say expected revenues will be in q4 2021, so technically we have to wait until they announce q4 in March 2022. Never thought of clarifying this to investors about why the delay. - rc has stated b4 that the lack of pr might due to pending regulatory approvals , but what the heck are they going to commercialize to begin with ? - I understand serology is not their priority but shows overall how much we can rely on this management. - stuck here coz of fomo
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities